Connecting Molecules to Medicine™
See What Makes Nexus Pharmaceuticals Different
Through our commitment to innovative R&D, Nexus Pharmaceuticals identifies off-patent and difficult to formulate molecules that can be developed, improved upon, and commercialized to advance industry standards and deliver on critical medical needs.
Opening in Summer 2021
State-of-the-Art Sterile Injectable Manufacturing Facility
Located in Pleasant Prairie, Wisconsin, we broke ground in 2019 to build Project Tomorrow, a state-of-the-art sterile injectable manufacturing facility to support the production and supply of injectable drugs in various therapeutic areas including anesthesiology, oncology, cardiology, and neurology. We plan to invest $250 million over the next ten years and create over 400 jobs in total.
I am writing with regards to the Opinion piece titled, “Our Drug Supply Is Sick. How Can We Fix It?” (Sept. 18, 2021). As the writer clearly highlights, the U.S. generic pharmaceutical industry is facing a crisis. Our company, Nexus Pharmaceuticals, Inc., is leading...
Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial. The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No. 11,090,278, on August 17, 2021.
On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow—the company’s new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin. Wisconsin Governor Tony Evers and U.S. Representative Bryan Steil (WI-01) attended the Project Tomorrow Grand Opening event.
Find out what we’re about
Discover more about Nexus Pharmaceuticals and get in touch today!